

# Essential Thrombocythemia Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight

*DelveInsight's Essential Thrombocythemia Market report offers an in-depth understanding of the epidemiology and market trends in the 7MM.*

LAS VEGAS, NEVADA, UNITED STATES, July 4, 2024 /EINPresswire.com/ -- DelveInsight's "Essential

Thrombocythemia Market Insights, Epidemiology, and Market Forecast-2034" report offers an in-depth understanding of the Essential Thrombocythemia, historical and

forecasted epidemiology as well as the Essential Thrombocythemia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Essential Thrombocythemia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; [Essential Thrombocythemia Market Forecast](#)

Some of the key facts of the Essential Thrombocythemia Market Report:

The Essential Thrombocythemia market size is anticipated to grow with a significant CAGR during the study period (2020-2034)

In January 2024, Merck announced the start of a pivotal Phase III trial for bomedemstat aimed at treating specific patients with Essential Thrombocythemia.

In January 2023, Merck has acquired Imago BioSciences, a clinical-stage biopharmaceutical company focused on developing new treatments for myeloproliferative neoplasms and other bone marrow diseases.

A study by Thompson et al. estimated the prevalence of Essential Thrombocythemia (ET). This research involved 237 patients and found an estimated prevalence of approximately 18 cases per 100,000 per year.



Essential Thrombocythemia Market

In France, there are approximately 1 to 2.5 new cases per 100,000 inhabitants each year. Additionally, the prevalence is around 1 case per 3,330 people.

A study by Harrison et al. estimated the distribution of ET patients by risk category. Low-risk patients made up about 22% of cases, intermediate-risk patients accounted for 16%, and high-risk patients comprised 20%. Additionally, around 42% of patients were not classified at the time of diagnosis.

Key Essential Thrombocythemia Companies: Merck Sharp & Dohme LLC, PharmaEssentia, CTI BioPharma, Incyte Corporation, Constellation Pharmaceuticals, GlaxoSmithKline, Syntara, Kartos Therapeutics, and others

Key Essential Thrombocythemia Therapies: Bomedemstat, IMG-7289, Ropoginterferon alfa-2b, Ruxolitinib, Pacritinib, INCB000928, Pelabresib, MMB, PXS-5505, KRT-232, and others

The Essential Thrombocythemia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Essential Thrombocythemia pipeline products will significantly revolutionize the Essential Thrombocythemia market dynamics.

#### Essential Thrombocythemia Overview

Essential thrombocythemia (ET) is a chronic blood disorder characterized by the overproduction of platelets (thrombocytes) by the bone marrow. Platelets are essential for blood clotting, but in ET, their excessive number can lead to an increased risk of abnormal blood clot formation (thrombosis), bleeding complications, or both.

Get a Free sample for the Essential Thrombocythemia Market Forecast, Size & Share Analysis Report:

[https://www.delveinsight.com/report-store/essential-thrombocythemia-et-market-insights?utm\\_source=einpresswire&utm\\_medium=pressrelease&utm\\_campaign=gpr](https://www.delveinsight.com/report-store/essential-thrombocythemia-et-market-insights?utm_source=einpresswire&utm_medium=pressrelease&utm_campaign=gpr)

#### Essential Thrombocythemia Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

#### Essential Thrombocythemia Epidemiology Segmentation:

The Essential Thrombocythemia market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

Total Prevalence of Essential Thrombocythemia

Prevalent Cases of Essential Thrombocythemia by severity

## Gender-specific Prevalence of Essential Thrombocythemia Diagnosed Cases of Episodic and Chronic Essential Thrombocythemia

Download the report to understand which factors are driving Essential Thrombocythemia epidemiology trends @ [Essential Thrombocythemia Epidemiology Forecast](#)

### Essential Thrombocythemia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Essential Thrombocythemia market or expected to get launched during the study period. The analysis covers Essential Thrombocythemia market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Essential Thrombocythemia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

### Essential Thrombocythemia Therapies and Key Companies

Bomedemstat: Merck Sharp & Dohme LLC

IMG-7289: The University of Texas Health Science Center

Ropeginterferon alfa-2b: PharmaEssentia

Ruxolitinib: Massachusetts General Hospital

Pacritinib: CTI BioPharma

INCB000928: Incyte Corporation

Pelabresib: Constellation Pharmaceuticals

MMB: GlaxoSmithKline

PXS-5505: Syntara

KRT-232: Kartos Therapeutics

### Essential Thrombocythemia Market Strengths

The World Health Organization (WHO) revised the criteria for diagnosing ET in 2016, providing clear guidelines for identification.

The revised-IPSET-t classification helps stratify thrombotic risk, aiding in treatment decisions.

### Essential Thrombocythemia Market Opportunities

Ongoing research aims to identify disease-modifying drugs that can prevent progression to more aggressive myeloid neoplasms, especially in younger patients.

As understanding of ET improves, novel therapies may emerge to enhance patient outcomes.

### Scope of the Essential Thrombocythemia Market Report

Study Period: 2020–2034

Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

Key Essential Thrombocythemia Companies Merck Sharp & Dohme LLC, PharmaEssentia, CTI BioPharma, Incyte Corporation, Constellation Pharmaceuticals, GlaxoSmithKline, Syntara, Kartos Therapeutics, and others

Key Essential Thrombocythemia Therapies: Bomedemstat, IMG-7289, Ropeginterferon alfa-2b, Ruxolitinib, Pacritinib, INCB000928, Pelabresib, MMB, PXS-5505, KRT-232, and others

Essential Thrombocythemia Therapeutic Assessment: Essential Thrombocythemia current marketed and Essential Thrombocythemia emerging therapies

Essential Thrombocythemia Market Dynamics: Essential Thrombocythemia market drivers and Essential Thrombocythemia market barriers

Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

Essential Thrombocythemia Unmet Needs, KOL's views, Analyst's views, Essential Thrombocythemia Market Access and Reimbursement

To know more about Essential Thrombocythemia companies working in the treatment market, visit @ [Essential Thrombocythemia Clinical Trials and Therapeutic Assessment](#)

## Table of Contents

1. Essential Thrombocythemia Market Report Introduction
2. Executive Summary for Essential Thrombocythemia
3. SWOT analysis of Essential Thrombocythemia
4. Essential Thrombocythemia Patient Share (%) Overview at a Glance
5. Essential Thrombocythemia Market Overview at a Glance
6. Essential Thrombocythemia Disease Background and Overview
7. Essential Thrombocythemia Epidemiology and Patient Population
8. Country-Specific Patient Population of Essential Thrombocythemia
9. Essential Thrombocythemia Current Treatment and Medical Practices
10. Essential Thrombocythemia Unmet Needs
11. Essential Thrombocythemia Emerging Therapies
12. Essential Thrombocythemia Market Outlook
13. Country-Wise Essential Thrombocythemia Market Analysis (2020–2034)
14. Essential Thrombocythemia Market Access and Reimbursement of Therapies
15. Essential Thrombocythemia Market Drivers
16. Essential Thrombocythemia Market Barriers
17. Essential Thrombocythemia Appendix
18. Essential Thrombocythemia Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

## About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Gaurav Bora

DelveInsight Business Research

+1 469-945-7679

[email us here](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/725222068>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.